Skip to main content
Laboratorios Farmaceuticos Rovi S.A. logo

Laboratorios Farmaceuticos Rovi S.A. — Investor Relations & Filings

Ticker · ROVI ISIN · ES0157261019 LEI · 95980020140005936480 MC Manufacturing
Open in API
Filings indexed 245 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country ES Spain
Listing MC ROVI

About Laboratorios Farmaceuticos Rovi S.A.

https://www.rovi.es/en/

Laboratorios Farmaceuticos Rovi S.A. is a specialized pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company focuses on small molecule drugs and specialty biologics. Its portfolio of licensed prescription pharmaceuticals targets therapeutic areas including thrombosis, cardiovascular, osteoarticular, and pneumology. In addition to its own product pipeline, Rovi provides contract manufacturing services to third parties, leveraging its integrated development and production capabilities.

Recent filings

Filing Released Lang Actions
La Compañía hace pública la presentación relativa a los resultados financieros del primer trimestre de 2026
Regulatory Filings
2026-05-06 Spanish
La Compañía hace público el comunicado de prensa relativo a los resultados financieros del primer trimestre de 2026
Regulatory Filings
2026-05-06 Spanish
La Sociedad informa sobre el acuerdo de convocatoria de su Junta General Ordinaria de Accionistas 2026.
Regulatory Filings
2026-05-06 Spanish
La Sociedad informa sobre el acuerdo de convocatoria de su Junta General Ordinaria de Accionistas 2026.
Regulatory Filings
2026-05-06 Spanish
Operaciones sobre acciones propias efectuadas en el primer trimestre de 2026 en el marco del contrato de liquidez
Transaction in Own Shares Classification · 100% confidence The document is a communication addressed to the Comisión Nacional del Mercado de Valores (CNMV) in Spain, referencing compliance with article 227 of the Ley 6/2023 regarding securities markets and investment services. It details operations on own shares (acciones propias) during the first quarter of 2026 under a liquidity contract, including detailed tables of purchases and sales of shares, cash balances, and transaction prices. The document is focused on reporting transactions related to the company's own shares under a liquidity contract, which aligns with reporting on transactions in own shares. There is no indication that this is a full financial report, earnings release, or other types of filings. The document is not a brief announcement but a detailed report of share transactions. Therefore, the most appropriate classification is "Transaction in Own Shares (POS)".
2026-04-07 Portuguese
ROVI informa del cierre del contrato de compraventa de activos (Asset Purchase Agreement) suscrito en septiembre de 2025 y relativo a la adquisición de una planta de fabricación de medicamentos en Pho
M&A Activity Classification · 95% confidence The document is a regulatory announcement submitted to the Spanish CNMV (“Comisión Nacional del Mercado de Valores”) under Article 227, informing the market that ROVI’s subsidiary ROIS Phoenix has completed an Asset Purchase Agreement with Bristol Myers Squibb to acquire a manufacturing plant and related assets. It describes the consummation of the contract, the strategic rationale, and related manufacturing agreement—classic M&A transaction disclosure. It is not an earnings release, not a full report, and not a notice of dividend, but a corporate transaction announcement. Therefore it is classified as M&A Activity (Code: TAR).
2026-04-01 Spanish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.